Diffusion Tensor Weighted MRI in Alzheimer's Disease Modifying Treatment Effects of Galantamine (Reminyl®)
Status:
Unknown status
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Alzheimer's disease (AD) is characterized by progressive subcortical and cortical neuronal
degeneration. AD patients differ in the time course of neuronal degeneration and accompanying
cognitive decline.
With recent advances in MR imaging, including optimized data acquisition and processing
techniques, tools that are especially well suited for tracking long-term pathological changes
as well as drug treatment effects have become available. In addition to structural imaging,
new acquisition and analysis techniques have been developed to determine integrity of
subcortical fiber tracts in vivo.
In the present project we propose to determine predictors of disease progression and
treatment response and investigate potential treatment effects on structural disease
progression, covering the continuum from axonal degeneration to cortical neuronal loss taking
advantage of recent advances in MRI acquisition and analysis techniques.